FDA Approves Verastem’s Groundbreaking Ovarian Cancer Treatment
Verastem reports that around 80,000 women worldwide are living with low-grade serous ovarian cancer (LGSOC). The company added that the new U.S. approval leads to an initial opportunity of reaching around 1800 patients. LGSOC disproportionately affects younger women and has poor response rates to chemotherapy.
Read The Full Blog:
https://www.coherentmarketinsights.com/news/fda-approves-verastems-groundbreaking-ovarian-cancer-treatment-1248
Verastem reports that around 80,000 women worldwide are living with low-grade serous ovarian cancer (LGSOC). The company added that the new U.S. approval leads to an initial opportunity of reaching around 1800 patients. LGSOC disproportionately affects younger women and has poor response rates to chemotherapy.
Read The Full Blog:
https://www.coherentmarketinsights.com/news/fda-approves-verastems-groundbreaking-ovarian-cancer-treatment-1248
FDA Approves Verastem’s Groundbreaking Ovarian Cancer Treatment
Verastem reports that around 80,000 women worldwide are living with low-grade serous ovarian cancer (LGSOC). The company added that the new U.S. approval leads to an initial opportunity of reaching around 1800 patients. LGSOC disproportionately affects younger women and has poor response rates to chemotherapy.
Read The Full Blog:
https://www.coherentmarketinsights.com/news/fda-approves-verastems-groundbreaking-ovarian-cancer-treatment-1248
0 Comments
0 Shares
16 Views
0 Reviews
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek